Navigation Links
Experimental Psoriasis Drug Bests Older Treatment
Date:10/27/2011

By Serena Gordon
HealthDay Reporter

WEDNESDAY, Oct. 26 (HealthDay News) -- An experimental psoriasis treatment performed significantly better than the commonly prescribed medication methotrexate in a new clinical trial.

The drug briakinumab reduced psoriasis symptoms by at least 75 percent in nearly 82 percent of those taking it, compared to just 40 percent of those on methotrexate. But serious side effects were more common among the briakinumab users.

"Very high levels of response" were observed and maintained throughout the study period, said lead researcher Dr. Kristian Reich, a professor of dermatology at the University of Gottingen and a managing partner at Dermatologikum Hamburg, both in Germany.

Results of the study are published in the Oct. 27 issue of the New England Journal of Medicine. The study was funded by the drug's manufacturer, Abbott Laboratories.

Psoriasis affects about 5 million Americans, according to the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The disease causes patches of thick, red, inflamed skin that have silvery scales. Psoriasis can affect any part of the body, including the skin, nails, genitals and inside the mouth, according to NIAMS.

The current study included 317 people with moderate to severe psoriasis. The study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.

Nearly half of the study participants were randomly selected to receive injections of briakinumab at a dose of 200 milligrams (mg) for the first and fourth week of the study, and 100 mg at week eight and every four weeks thereafter. The study lasted one year. The remaining volunteers were given between 5 mg and 25 mg of oral methotrexate weekly.

After six months, nearly 82 percent of those in the briakinumab group had at least a 75 percent improvement in the psoriasis area-and-severity index (PASI), a commonly used measurement to assess the severity of psoriasis. Slightly less than 40 percent of those on methotrexate had a 75 percent improvement in their PASI score, according to the study.

After a year, about 66 percent of those taking briakinumab had a 75 percent improvement in their PASI score compared to almost 24 percent for those on methotrexate, according to the study.

Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.

More serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent). There were also two cases of cancer in people taking briakinumab and none in the methotrexate group. However, the researchers said these differences weren't statistically significant.

"Cancer risk is extremely hard to define, and this study was not powered to detect any difference in the risk of developing a malignancy," said Bebo.

He said that in an earlier trial of briakinumab, some unexplained major adverse cardiac events occurred. At the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research. In the current study, no serious cardiovascular events were reported.

Of the increased infections and cancers, Reich said, "Although these differences were not statistically significant, they lead to questions regarding a favorable risk-benefit profile of the drug."

Research on briakinumab is continuing. An ongoing three-year trial involves 248 people from the current study.

For people living with psoriasis, Bebo said the message from this study is that "dramatic progress has been made from where we were just five years ago."

More information

Learn more about psoriasis treatments from the National Psoriasis Foundation.

SOURCES: Kristian Reich, M.D., professor, dermatology, University of Gottingen, and managing partner, Dermatologikum Hamburg, Germany; Bruce Bebo, Ph.D., director, research and medical programs, National Psoriasis Foundation, Portland, Ore.; Oct. 27, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Psoriasis Drug Bests Older Treatment
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: